Michael Yee
Stock Analyst at UBS
(3.81)
# 715
Out of 5,113 analysts
108
Total ratings
48.05%
Success rate
11%
Average return
Main Sectors:
Stocks Rated by Michael Yee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $535 → $545 | $477.50 | +14.14% | 6 | Jan 26, 2026 | |
| GILD Gilead Sciences | Maintains: Buy | $145 → $155 | $140.53 | +10.30% | 5 | Jan 26, 2026 | |
| AMGN Amgen | Maintains: Buy | $380 → $390 | $342.70 | +13.80% | 7 | Jan 26, 2026 | |
| VTYX Ventyx Biosciences | Downgrades: Neutral | $20 → $14 | $13.96 | +0.29% | 3 | Jan 8, 2026 | |
| ACLX Arcellx | Assumes: Buy | $100 | $68.42 | +46.16% | 1 | Jan 7, 2026 | |
| IDYA IDEAYA Biosciences | Assumes: Buy | $50 | $33.88 | +47.58% | 1 | Jan 7, 2026 | |
| DNLI Denali Therapeutics | Assumes: Buy | $25 | $20.51 | +21.89% | 3 | Jan 7, 2026 | |
| IMCR Immunocore Holdings | Assumes: Buy | $24 → $55 | $33.00 | +66.67% | 2 | Jan 7, 2026 | |
| IVA Inventiva | Assumes: Buy | $3 → $12 | $6.89 | +74.17% | 1 | Jan 7, 2026 | |
| ANAB AnaptysBio | Assumes: Buy | $20 → $70 | $48.50 | +44.33% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $33.79 | +47.97% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $43.47 | +38.03% | 4 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $18 | $14.86 | +21.13% | 3 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $4.49 | +55.90% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $34.42 | +45.26% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $25.17 | +78.78% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $10 | $5.37 | +86.22% | 4 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $35.90 | +67.15% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $25.93 | +92.86% | 4 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $29.02 | -3.50% | 3 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.46 | +447.61% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $17.25 | +102.90% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $8.28 | +141.55% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $46 → $65 | $54.76 | +18.70% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $220 → $240 | $219.18 | +9.50% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $130 → $185 | $173.22 | +6.80% | 6 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $25 | $25.96 | -3.70% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $1,080 → $1,250 | $1,006.00 | +24.25% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $3 | $1.40 | +114.41% | 5 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $55 | $44.69 | +23.07% | 8 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $385 | $565.99 | -31.98% | 4 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $3 | $5.19 | -42.20% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $60 → $20 | $15.13 | +32.19% | 8 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $30 | $3.45 | +769.57% | 4 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $9.48 | +216.46% | 3 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 | $26.58 | +351.47% | 2 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $73.05 | -58.93% | 1 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $77 | $21.69 | +255.00% | 2 | Nov 8, 2018 |
Vertex Pharmaceuticals
Jan 26, 2026
Maintains: Buy
Price Target: $535 → $545
Current: $477.50
Upside: +14.14%
Gilead Sciences
Jan 26, 2026
Maintains: Buy
Price Target: $145 → $155
Current: $140.53
Upside: +10.30%
Amgen
Jan 26, 2026
Maintains: Buy
Price Target: $380 → $390
Current: $342.70
Upside: +13.80%
Ventyx Biosciences
Jan 8, 2026
Downgrades: Neutral
Price Target: $20 → $14
Current: $13.96
Upside: +0.29%
Arcellx
Jan 7, 2026
Assumes: Buy
Price Target: $100
Current: $68.42
Upside: +46.16%
IDEAYA Biosciences
Jan 7, 2026
Assumes: Buy
Price Target: $50
Current: $33.88
Upside: +47.58%
Denali Therapeutics
Jan 7, 2026
Assumes: Buy
Price Target: $25
Current: $20.51
Upside: +21.89%
Immunocore Holdings
Jan 7, 2026
Assumes: Buy
Price Target: $24 → $55
Current: $33.00
Upside: +66.67%
Inventiva
Jan 7, 2026
Assumes: Buy
Price Target: $3 → $12
Current: $6.89
Upside: +74.17%
AnaptysBio
Jan 7, 2026
Assumes: Buy
Price Target: $20 → $70
Current: $48.50
Upside: +44.33%
Jan 7, 2026
Initiates: Buy
Price Target: $50
Current: $33.79
Upside: +47.97%
Jan 7, 2026
Initiates: Buy
Price Target: $60
Current: $43.47
Upside: +38.03%
Jan 7, 2026
Initiates: Neutral
Price Target: $18
Current: $14.86
Upside: +21.13%
Jan 7, 2026
Initiates: Buy
Price Target: $7
Current: $4.49
Upside: +55.90%
Jan 7, 2026
Initiates: Buy
Price Target: $50
Current: $34.42
Upside: +45.26%
Jan 7, 2026
Initiates: Buy
Price Target: $45
Current: $25.17
Upside: +78.78%
Jan 7, 2026
Initiates: Neutral
Price Target: $10
Current: $5.37
Upside: +86.22%
Jan 7, 2026
Initiates: Buy
Price Target: $60
Current: $35.90
Upside: +67.15%
Jan 7, 2026
Initiates: Buy
Price Target: $50
Current: $25.93
Upside: +92.86%
Jan 7, 2026
Initiates: Neutral
Price Target: $28
Current: $29.02
Upside: -3.50%
Jan 7, 2026
Initiates: Buy
Price Target: $8
Current: $1.46
Upside: +447.61%
Jan 7, 2026
Initiates: Buy
Price Target: $35
Current: $17.25
Upside: +102.90%
Jan 7, 2026
Initiates: Buy
Price Target: $20
Current: $8.28
Upside: +141.55%
Jan 7, 2026
Upgrades: Buy
Price Target: $46 → $65
Current: $54.76
Upside: +18.70%
Jan 7, 2026
Assumes: Neutral
Price Target: $220 → $240
Current: $219.18
Upside: +9.50%
Jan 7, 2026
Assumes: Neutral
Price Target: $130 → $185
Current: $173.22
Upside: +6.80%
Jan 7, 2026
Assumes: Neutral
Price Target: $25
Current: $25.96
Upside: -3.70%
Jan 7, 2026
Assumes: Buy
Price Target: $1,080 → $1,250
Current: $1,006.00
Upside: +24.25%
Mar 6, 2025
Upgrades: Buy
Price Target: $2 → $3
Current: $1.40
Upside: +114.41%
Oct 15, 2024
Maintains: Hold
Price Target: $65 → $55
Current: $44.69
Upside: +23.07%
Jul 17, 2024
Initiates: Buy
Price Target: $385
Current: $565.99
Upside: -31.98%
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $5.19
Upside: -42.20%
Oct 25, 2023
Downgrades: Hold
Price Target: $60 → $20
Current: $15.13
Upside: +32.19%
Feb 12, 2021
Downgrades: Hold
Price Target: $40 → $30
Current: $3.45
Upside: +769.57%
Feb 12, 2021
Upgrades: Buy
Price Target: $15 → $30
Current: $9.48
Upside: +216.46%
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $26.58
Upside: +351.47%
Sep 14, 2020
Initiates: Buy
Price Target: $30
Current: $73.05
Upside: -58.93%
Nov 8, 2018
Assumes: Buy
Price Target: $77
Current: $21.69
Upside: +255.00%